



Press Release

Gen9 and Arzeda Announce Supply Agreement for Synthetic DNA

Arzeda joins Gen9's MAP program to purchase mass quantities of high-quality synthetic DNA for development of sustainable industrial chemicals

CAMBRIDGE, Mass., and SEATTLE, Wash., April 20, 2016 – Gen9 and Arzeda today announced an agreement for the supply of megabase quantities of synthetic DNA that will enable Arzeda to accelerate development of novel molecules for its own products as well as those of its partners. The collaboration is part of Gen9's MAP program, designed to provide industrial users of synthetic DNA with access to game-changing economics for synthetic DNA.

"Through Gen9's MAP we have access to millions of base pairs of DNA, enabling us to ramp up the development of novel and valuable molecules to help make the food we eat, the products we buy and the air we breathe less toxic and more sustainable," said Alexandre Zanghellini, Arzeda's co-founder and CEO. "We are revolutionizing the way chemicals are produced and Gen9's capabilities are a perfect fit for our technology."

The Gen9 Multiplex Access Partnership (MAP) program is fueled by Gen9's BioFab® DNA synthesis platform enabling the manufacture of mass quantities of high quality, long-length clonal DNA. Arzeda will utilize Gen9 synthetic DNA as part of its program to create a portfolio of enzymes and specialty chemicals for polymers, novel crop traits, pharmaceuticals, industrial chemicals and other advanced materials. Arzeda's proprietary technology combines computational enzyme and pathway design with state-of-the-art bioengineering to create entirely novel designer cell factories capable of industry-scale chemical production.

"We see synthetic biology as a foundational approach for enormous value creation, whether it be reducing the environmental footprint of a chemical manufacturing process or engineering a pathway to more efficiently and cost-effectively produce high value molecules," said Kevin Munnely, President and CEO of Gen9. "We are thrilled to work with Arzeda and look forward to the critical advancements our combined efforts will drive."

More information is available on the web at www.gen9bio.com or www.arzeda.com

About Gen9

Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels.



Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Massachusetts. Visit Gen9 at www.gen9bio.com.

About Arzeda

Since 2008 Arzeda has been harnessing the power of computational and synthetic biology to create new enzymes and chemical products that can compete on cost, performance and sustainability. In partnership with Fortune 500 companies and industrial leaders, the company has developed a portfolio of enzymes and specialty chemicals for polymers, advanced materials and health and nutrition products. Arzeda's proprietary platform and validation process rapidly creates "cell factories" that can be used at industrial scales to solve problems and create opportunities that otherwise would be impossible. More information is available online at www.arzeda.com and [twitter.com/@ArzedaCo](https://twitter.com/ArzedaCo).

Media Contacts

Arzeda

John Williams, Scoville PR for Arzeda

206-625-0075, jwilliams@scovillepr.com

Chempetitive Group for Gen9

Janice Foley

617-823-5555, jfoley@chempetitive.com